PDCD1 and neoplasm: Moreover, the suppression of NANOG expression in tumor cells converted the immune-refractory microenvironment into an immune-stimulatory microenvironment that facilitated antitumor immunity and overcame the resistance to anti–PD-1 therapy, as shown in Figure 2.